Previous Close | 92.31 |
Open | 0.00 |
Bid | 91.40 x N/A |
Ask | 0.00 x N/A |
Day's Range | 0.00 - 0.00 |
52 Week Range | |
Volume | |
Avg. Volume | 1,401,016 |
Market Cap | 214.302B |
Beta (5Y Monthly) | 0.49 |
PE Ratio (TTM) | 29.12 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.20 (3.78%) |
Ex-Dividend Date | Mar 09, 2023 |
1y Target Est | N/A |
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.